NCT04733430Recruiting
LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice
Source: ClinicalTrials.gov · Last updated 18 Mar 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 18 Jan 2021
- Start date
- 17 Apr 2020
- Primary completion date
- 30 Apr 2030
- Lead sponsor
- Karl Landsteiner Institute for Lung Research and Pneumological Oncology
- Diseases
- Lung cancer
- NCT number
- NCT04733430
What you commit to
- Study type: Observational
- Planned participants: 500
- From 17 Apr 2020 to the primary completion date, 30 Apr 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Informed consent
- Histologically confirmed lung cancer
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
Age in the registry: 18 years to 125 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie Coordinator of this site? Confirm its status | Vienna | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.